Home > Urology > Dapagliflozin again shows kidney, cardiovascular benefit beyond glucose control

Dapagliflozin again shows kidney, cardiovascular benefit beyond glucose control

Journal
New England Journal of Medicine
Reuters Health - 24/09/2020 - The diabetes drug dapagliflozin can prevent decline in kidney function among patients with chronic kidney disease, according to new results from the DAPA-CKD trial. Researchers following 4,304 volunteers for a median of 2.4 years saw kidney function decline in 9.2% of dapagliflozin recipients compared with 14.5% of placebo recipients, a reduction of 39% (P<0.001). "Decline" was defined as a drop of at least 50% in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or death from renal or cardiovascular causes. When cardiovascular deaths were taken out of the mix, the drug lowered the combined risk by 44% (P<0.001) compared with placebo. "The effects of dapagliflozin were similar in participants with type 2 diabetes and in those without," said the team, led by Hiddo Heerspink of the University of Groningen in the Netherlands. The study, published in The New England Journal of Medicine and pre...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on